Importantly, recombinant LIF could activate STAT3 and downregulate RET and induce tumor suppression in human MTC cells xenografted in mice [111], suggesting its potential as a therapeutic reagent to treat MTC. Here, LIF is linked to medullary thyroid gland carcinoma.